Dana-Farber Cancer Institute

Articles

Kimberly Stegmaier Named as Pediatric Oncology Chair at Dana-Farber

February 21st 2025

Kimberly Stegmaier, MD, was recently named Chair of Pediatric Oncology at Dana-Farber Cancer Institute.

Cancer Vaccine Shows Promise for Patients With Stage III and IV Kidney Cancer

February 10th 2025

Patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma generated successful responses after a personalized cancer vaccine.

AI Model Learns Generalized 'Language' of Regulatory Genomics, Predicts Cellular Stories

February 5th 2025

The model, called EpiBERT, was inspired by BERT, a deep learning model designed to understand and generate human-like language.

Blood Test Could Guide Use of Anti-Inflammatory Drug Celecoxib to Reduce Risk of Colon Cancer Recurrence

January 28th 2025

Patients with evidence of residual cancer in their blood after surgery, may benefit from adding of celecoxib to post surgery treatment.

PET Probe Images Inflammation With High Sensitivity and Selectivity

January 24th 2025

Researchers at Dana-Farber Cancer Institute have developed a breakthrough method to detect inflammation in the body using positron emission tomography (PET) imaging.

Dana-Farber Brigham Cancer Center Recognized for Exceptional Outcomes in Adult Donor Stem Cell Transplants for Fifth Consecutive Year

January 22nd 2025

Stem cell transplant programs at the Dana-Farber Brigham Cancer Center received outstanding reviews from the CIBMTR.

Dana-Farber and Gustave Roussy Announce 2025 Transatlantic Exchange Scientific Program to Focus on Radioligand Therapy

January 16th 2025

Dana-Farber Cancer Institute and Gustave Roussy have announced that the topic of the Fourth Transatlantic Exchange in Oncology Conference will be “Radiopharmaceutical Therapy Meets Oncology.”

Dana-Farber Launches Center for RAS Therapeutics to Target the RAS Oncogene in Cancer

January 8th 2025

Dana-Farber Cancer Institute will launch the Center for RAS Therapeutics to advance scientific investigation and clinical care for RAS-driven cancers.

Dana-Farber Researchers to Present Findings at 2024 San Antonio Breast Cancer Symposium

December 11th 2024

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 47th annual San Antonio Breast Cancer Symposium

Predictive Tool for Melanoma Could Guide Immunotherapy Choices

December 3rd 2024

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.

Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers for 2024

November 21st 2024

Dana-Farber Cancer Institute announced that 42 of its researchers have been named to the Highly Cited Researchers list of 2024.

First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber

November 18th 2024

Investigators are opening a trial to evaluate a novel type of immune cellular therapy in patients with recurrent, platinum-resistant ovarian cancer.

Two Dana-Farber Cancer Institute Faculty Members Elected to the National Academy of Medicine

November 1st 2024

David Pellman, MD, and Matthew Vander Heiden, MD, PhD of Dana-Farber Cancer Institute have been named to the National Academy of Medicine.

Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives

October 28th 2024

Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.

Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a Row

October 25th 2024

U.S. News & World Report has recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #2 pediatric cancer program in the nation.

Dana-Farber Cancer Institute Delivers ‘Simple Immediate Impact’ to Patient Comfort Using Weighted Blankets

October 14th 2024

Dana-Farber Cancer Institute has used weighted blankets to aid in patient care.

Study Finds Doctors and Patients Interested in Environmental Impact of Health Care Decisions

October 9th 2024

In focus groups conducted in the US, doctors and patients expressed openness to considering environmental factors when discussing treatment options.

Cigall Kadoch, PhD, Wins Prestigious Blavatnik National Award

October 7th 2024

Cigall Kadoch, PhD, has been named as the Laureate of the Blavatnik National Awards for Young Scientists in the field of life sciences.

Criteria for Cancer Clinical Trials and Treatment Regimens Place Patients of African and Middle Eastern Ancestry at a Disadvantage Due to Natural Blood Test Variability, Study Finds

October 4th 2024

Clinical trials may be inappropriately excluding some people with "Duffy-null phenotype," a trait found in people of African or Middle Eastern descent.

ADC Found Effective Against Brain Metastases in Patients with HER2+ Breast Cancer

September 26th 2024

T-DXd shows substantial antitumor activity in brain metastases in patients with HER2-positive breast cancer in a major international clinical trial.